BOB Capital Markets has reiterated its BUY recommendation on Lupin with a revised target price of Rs 2,900, implying an upside potential of nearly 22% from the current market price of Rs 2,380. The brokerage upgraded earnings estimates after Lupin delivered a sharp earnings surprise in Q4FY26, supported by robust growth across the US, India, and emerging markets. The company’s margin profile strengthened significantly due to a superior product mix, cost efficiencies, and accelerating traction in complex generics and specialty therapies. Analysts now believe Lupin is steadily progressing toward becoming a USD 1 billion EBITDA company by FY29, driven by strong execution across geographies and a deep launch pipeline.

Q4FY26 Performance Delivers A Major Earnings Shock

Lupin’s quarterly numbers comfortably surpassed Street expectations, reinforcing investor confidence in the company’s transformation into a higher-margin pharmaceutical player. Revenue for Q4FY26 surged 31.9% year-on-year to Rs 74.7 billion, while EBITDA jumped 68% to Rs 21.7 billion. Profitability expanded sharply, with EBITDA margins climbing to 29%, representing a 625 basis-point improvement over the previous year.

Adjusted profit after tax stood at Rs 12.8 billion, while reported PAT rose 89% YoY to Rs 14.6 billion due to forex gains and litigation settlements categorized as exceptional income. The strong operational beat was largely driven by better pricing dynamics in the US market, lower competitive intensity in key products, and higher profitability from branded formulations.

US Business Continues To Anchor Growth Momentum

The US market remains Lupin’s largest growth engine, with constant-currency sales touching an all-time high of USD 370 million during the quarter. The company benefited from slower-than-expected generic erosion in critical products such as Tolvaptan and Mirabegron, both of which continue to enjoy favorable market penetration dynamics.

Management acknowledged that competition in these products is expected to intensify beginning FY27, but the brokerage remains confident that upcoming launches will offset pricing pressure. Lupin plans nearly 20 new launches in the US market, including two lucrative First-to-File opportunities.

The pipeline remains particularly strong in respiratory products, complex injectables, biosimilars, and 505(b)(2) products. Key catalysts include Revicti, Saxenda, Pegfilgrastim, Ranibizumab, Dulera, and Apixaban formulations. The company also expects biosimilar revenue to triple in FY27.

Domestic Formulations Business Returns To Double-Digit Expansion

Lupin’s India business regained momentum after four quarters of subdued performance. Domestic sales increased 12% YoY to Rs 19 billion in Q4FY26, led by strong traction in prescription therapies. The company continued to outperform the Indian Pharmaceutical Market across diabetes, respiratory, and cardiac therapies.

One of the biggest highlights was the successful launch of generic Semaglutide under the brands Semanext and Livarize. Management stated that Lupin has already emerged among the top three players in the generic Semaglutide segment in India, aided by strong acceptance of its pen device.

The company also continues to deepen its chronic therapy exposure, which now contributes 66% of domestic sales. Over the next several years, Lupin aims to increase this contribution to 70%, improving business predictability and margin stability.

Emerging Markets And Europe Add A New Layer Of Strength

Brazil emerged as a standout geography for Lupin’s emerging markets business, with sales in the region jumping 113% YoY due to strong traction in Dapagliflozin. The company now plans to expand its diabetes and metabolic portfolio further with Empagliflozin and Semaglutide launches across Brazil and South Africa.

Emerging market revenue grew 49% YoY during the quarter to Rs 9.9 billion, supported by robust contributions from Brazil, Mexico, South Africa, and the Philippines.

Meanwhile, the acquisition of VISUfarma is expected to strengthen Lupin’s ophthalmology footprint in Europe. The acquisition provides strategic access to Spain and Italy while enhancing the company’s specialty product distribution platform across Europe. Management expects the ophthalmology business to exceed USD 100 million in revenue over the next two to three years.

Balance Sheet Strength Opens Doors For Specialty Expansion

Lupin ended FY26 with a cash balance of Rs 5.6 billion, giving management flexibility to pursue acquisitions and licensing opportunities in high-margin specialty therapies. The company indicated interest in areas such as ophthalmology, pulmonology, rare neurology, and innovation-led chronic therapies.

Analysts believe this cash-rich position significantly improves Lupin’s ability to scale its specialty portfolio while maintaining healthy financial discipline. BOBCAPS also highlighted the possibility of inorganic growth initiatives as a key long-term valuation driver.

Valuation Outlook And Investment View

BOBCAPS has raised earnings estimates for FY27 and FY28 by 11% and 12%, respectively, citing sustained growth across geographies and strong visibility from complex generics launches.

At the current market price, Lupin trades at approximately 23.5x FY27 earnings and 21.2x FY28 earnings. BOBCAPS continues to value the company at 26x forward earnings and has rolled forward valuations to March 2028 to derive its revised target price of Rs 2,900.

Technical And Strategic Investor Takeaway

Lupin appears to be entering a structurally stronger earnings cycle, supported by expanding specialty exposure, a rising chronic portfolio, robust US execution, and improving global diversification. The company’s margin profile has strengthened materially over the last several quarters, while future growth catalysts remain abundant through FY28 and FY29.

Investors may closely monitor competitive intensity in key US products such as Mirabegron and Tolvaptan, regulatory approvals for complex generics, and execution of biosimilar launches. However, current operational momentum, healthy cash generation, and a diversified launch pipeline continue to support a constructive medium-term outlook for the stock.